Trisomy silencing by XIST normalizes Down syndrome cell pathogenesis demonstrated for hematopoietic defects in vitro.

We previously demonstrated that an integrated XIST transgene can broadly repress one chromosome 21 in Down syndrome (DS) pluripotent cells. Here we address whether trisomy-silencing can normalize cell function and development sufficiently to correct cell pathogenesis, tested in an in vitro model of human fetal hematopoiesis, for which DS cellular phenotypes are best known. XIST induction in four transgenic clones reproducibly corrected over-production of megakaryocytes and erythrocytes, key to DS myeloproliferative disorder and leukemia. A contrasting increase in neural stem and iPS cells shows cell-type specificity, supporting this approach successfully rebalances the hematopoietic developmental program. Given this, we next used this system to extend knowledge of hematopoietic pathogenesis on multiple points. Results demonstrate trisomy 21 expression promotes over-production of CD43+ but not earlier CD34+/CD43-progenitors and indicates this is associated with increased IGF signaling. This study demonstrates proof-of-principle for this epigenetic-based strategy to investigate, and potentially mitigate, DS developmental pathologies.

Translating dosage compensation to trisomy 21.

Down's syndrome is a common disorder with enormous medical and social costs, caused by trisomy for chromosome 21. We tested the concept that gene imbalance across an extra chromosome can be de facto corrected by manipulating a single gene, XIST (the X-inactivation gene). Using genome editing with zinc finger nucleases, we inserted a large, inducible XIST transgene into the DYRK1A locus on chromosome 21, in Down's syndrome pluripotent stem cells. The XIST non-coding RNA coats chromosome 21 and triggers stable heterochromatin modifications, chromosome-wide transcriptional silencing and DNA methylation to form a 'chromosome 21 Barr body'. This provides a model to study human chromosome inactivation and creates a system to investigate genomic expression changes and cellular pathologies of trisomy 21, free from genetic and epigenetic noise. Notably, deficits in proliferation and neural rosette formation are rapidly reversed upon silencing one chromosome 21. Successful trisomy silencing in vitro also surmounts the major first step towards potential development of 'chromosome therapy'.

A cluster validity measure with outlier detection for support vector clustering.

This paper focuses on the development of an effective cluster validity measure with outlier detection and cluster merging algorithms for support vector clustering (SVC). Since SVC is a kernel-based clustering approach, the parameter of kernel functions and the soft-margin constants in Lagrangian functions play a crucial role in the clustering results. The major contribution of this paper is that our proposed validity measure and algorithms are capable of identifying ideal parameters for SVC to reveal a suitable cluster configuration for a given data set. A validity measure, which is based on a ratio of cluster compactness to separation with outlier detection and a cluster-merging mechanism, has been developed to automatically determine ideal parameters for the kernel functions and soft-margin constants as well. With these parameters, the SVC algorithm is capable of identifying the optimal number of clusters with compact and smooth arbitrary-shaped cluster contours for the given data set and increasing robustness to outliers and noise. Several simulations, including artificial and benchmark data sets, have been conducted to demonstrate the effectiveness of the proposed cluster validity measure for the SVC algorithm.